Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy.

Originally, VEN-HMA was tested in frail and elderly patients with newly diagnosed AML who historically had a very low chance of attaining remission with available therapies [[1]], and it produced a high response rate with low treatment-related mortality. Six (40%) patients had achieved CR and 9 (60%) had achieved CRi with initial therapy, including a negative minimal residual disease (MRD-) response in 9 patients, while 4 had persistent MRD disease during therapy. [Extracted from the article]